Liquid Biopsy Market
Geographically North America dominated global liquid biopsy market, with approximately half of the world’s procedures being done in the U.S. because of high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations such as China, and India in this region. Among all the procedures, oncology procedures has the highest market share in global liquid biopsy market due to higher prevalence of cancer patients.
This report identifies the global liquid biopsy market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global liquid biopsy market.
This report segments global liquid biopsy market on the basis of cancer type, Circulating Biomakers , end-user, and regional market as follows:
Liquid Biopsy Market, By cancer type: Lung, Breast, Colorectal, Prostate, Liver
The report has focused study on liquid biopsy market on basis of Circulating biomarker such as: Tumor Cells, Circulating Tumor DNA and other,
The report has focused study on liquid biopsy market on basis of End User such as: Reference Laboratory, Research Centers
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the liquid biopsy market. Some of the major companies’ profiles in detail are as follows:
F. Hoffmann-La Roche AG
Bio-Rad Laboratories Inc.
Janssen Diagnostics, LLC.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis
4. Liquid Biopsy Market– Market Forces
4.1.1. Increasing cases of new cancer patients
4.1.2. Benefits of Liquid Biopsy Over Surgical Biopsy
4.2.1. Low Sensitivity and Specificity
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Liquid Biopsy Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Liquid Biopsy Market, By Cancer Type
6.1. Lung Cancer
6.2. Breast Cancer
6.3. Colorectal Cancer
6.4. Prostate Cancer
6.5. Liver Cancer
6.6. Other Cancers
7. Liquid Biopsy Market, By Circulating Biomarker
7.1. Circulating Tumor Cells
7.2. Extracellular Vesicles
7.3. Circulating Tumor DNA (CTDNA)
7.4. Other Biomarkers
8. Liquid Biopsy Market, By End-User
8.1. Reference Laboratory,
8.2. Research Centers
9. Liquid Biopsy Market, By Geography
9.1.7. Rest of Europe
9.2. Asia Pacific
9.2.4. South Korea
9.2.5. Rest of Asia-Pacific
9.3. North America
9.4. Rest of the World (RoW)
9.4.2. Rest of RoW
10. Liquid Biopsy – Market Entropy
10.2. Technological Developments
10.3. Merger & Acquisitions, and Joint Ventures
10.4. Supply- Contract
11. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
11.1. Biocept, Inc.
11.3. F. Hoffmann-La Roche AG
11.4. Bio-Rad Laboratories Inc.
11.5. Myriad Genetics
11.6. Janssen Diagnostics, LLC.
11.7. Tr0vagene Inc.
11.8. Guardant Health Inc.
11.10. MDX Health SA
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12.3. Research Methodology
12.5. Compilation of Expert Insights